Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


Clinical outcomes of teriflunomide and polypharmacy in relapsing multiple sclerosis: a retrospective case-series

  • At: Seville (Spain) (2022)
  • Type: Poster
  • Poster code: HPS-049
  • By: LEONG, Nga Weng (E-Da Hospital, Taiwan China)
  • Co-author(s): Ms Nga Weng Leong, Department of Pharmacy (E-Da Hospital, Kaohsiung, Taiwan China)
    Mr Yung Jun Hung, Department of Pharmacy (E-Da Hospital, Kaohsiung, Taiwan China)
    Mrs Yi Ping Hsiang, Department of Pharmacy (E-Da Hospital, Kaohsiung, Taiwan China)
  • Abstract:

    Background
    Teriflunomide is a high-priced oral disease-modifying therapy (DMT) indicated for treatment of relapsing multiple sclerosis (MS). In addition, prescribing requires prior review by the National Health Insurance Administration in Taiwan. Therefore, medication utilization review is compulsory. Not only for disease progression and safety..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses